Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekter av et nettbasert støtteprogram for hjertestansoverlevere (CARDIS)

9. november 2026 oppdatert av: Ingela Thylén, Linkoeping University

Effekter av et nettbasert støtteprogram for hjertestansoverlevere: En randomisert kontrollert studie med prosessevaluering (CARDIS-studien)

The overall goal of this clinical trial is to learn if a web-based support programme can improve wellbeing in cardiac arrest survivors by helping them manage emotional, cognitive, and physical challenges. The study also explores how the programme is used and experienced in practice.

The main questions it aims to answer are:

  • Can access to a web-based support programme improve overall wellbeing in cardiac arrest survivors?
  • Can it also enhance quality of life, cognitive function, life satisfaction, and sleep, while reducing anxiety, depression, post-traumatic stress, and fatigue? Researchers will compare cardiac arrest survivors who receive a web-based support programme in addition to standard care with those who receive standard care alone, to see if the programme improves wellbeing and other health outcomes. After the study, the control group will also gain access to the programme.

Participants will:

  • Be asked to complete online questionnaires at three time points: at the start of the study, after 3 months, and after 6 months.
  • Be encouraged to use a web-based support programme for 3 months, with unlimited access, at their own pace and according to their individual needs (intervention group only).

Studieoversikt

Status

Påmelding etter invitasjon

Detaljert beskrivelse

Cardiac arrest is a serious public health issue, affecting around 13,000 people annually in Sweden. Survivors often face long-term physical, cognitive, and emotional challenges, including anxiety, depression, fatigue, sleep disturbances, and post-traumatic stress. These difficulties can significantly impact daily life, and many survivors struggle to return to work or previous routines.

Although guidelines recommend follow-up within 1-3 months after hospital discharge, support is often fragmented and varies across regions. Survivors frequently report limited access to reliable information and emotional support. Research has shown that structured education and rehabilitation are essential for both survivors and their families, yet current care models rarely address these needs in a comprehensive way.

To help fill this gap, a web-based support programme was co-created in 2024-2025 by researchers, healthcare professionals, cardiac arrest survivors, and patient organizations. The programme includes educational modules, patient and family stories, videos, practical exercises, and tools for self-management and personal recovery planning. It also features a moderated chat forum for peer support. A feasibility study showed that the programme was easy to use and perceived as relevant and helpful.

The study begins with a pilot phase (n=10) to test study procedures, followed by a randomized controlled trial (RCT) with 120 participants across six Swedish regions. Participants are recruited during routine follow-up visit one month after discharge. All participants receive standard care. Those randomized to the intervention group gain access to the digital support programme for 12 weeks. The control group receives standard care and gains access to the programme after study completion.

Consent and data collection are handled digitally. Participants are asked to complete online surveys at baseline, 3 months, and 6 months. These surveys cover wellbeing, quality of life, sleep, fatigue, emotional health, and cognitive function. The study also collects usage data from the programme to understand how participants engage with the content. No physical tests or extra clinic visits are required.

The study aims to generate new knowledge about how digital tools can support recovery after cardiac arrest, improve wellbeing, and reduce healthcare burden by offering accessible, person-centered rehabilitation.

Studietype

Intervensjonell

Registrering (Antatt)

120

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Gothenburg, Sverige
        • Sahlgrenska Universitetssjukhuset
      • Gothenburg, Sverige
        • Östra sjukhuset
      • Helsingborg, Sverige
        • Helsingborgs lasarett
      • Kalmar, Sverige
        • Länssjukhuset
      • Linköping, Sverige
        • Universitetssjukhuset
      • Lund, Sverige
        • Skånes universitetssjukhus
      • Motala, Sverige
        • Lasarettet i Motala
      • Norrköping, Sverige
        • Vrinnevisjukhuset
      • Stockholm, Sverige
        • Capio S:t Görans sjukhus
      • Stockholm, Sverige
        • Karolinska universitetssjukhuset
      • Västerås, Sverige
        • Västmanlands sjukhus Västerås

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older
  • Survival of a cardiac arrest 1 to 3 months prior to enrollment
  • Access to a mobile phone, tablet, or computer with internet connection

Exclusion Criteria:

  • Insufficient language or cognitive ability to engage with a digital intervention and complete questionnaires in Swedish
  • Participation in another study involving the collection of patient-reported outcome measures (PROMs)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Nettbasert støtteprogram for hjertestansoverlevere

The intervention consists of a web-based support programme designed for individuals recovering from cardiac arrest. Participants in the intervention group receive access to the programme for 12 weeks. The programme includes educational modules, patient and family stories, videos, practical exercises (e.g., breathing techniques, fatigue management), tools for personal recovery planning, and a moderated chat forum for peer support. Participants can access the content at their own pace and according to their individual needs. The programme is delivered entirely online and does not require any physical visits or clinical procedures.

Ingen inngripen: Waitlist Control (Standard Care + Delayed Access)

Participants in this arm receive standard follow-up care according to national guidelines. They do not have access to the digital support programme during the study period. However, they are placed on a waitlist and are offered access to the programme after study completion.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in Overall Wellbeing at 3 months.
Tidsramme: From baseline to 3 months after enrollment.

The Questionnaire on Well-Being is a tool designed to capture subjective well-being. It consists of 18 questions, each rated from 0 to 4, which are added together to give a total score between 0 and 72. Higher scores reflect greater perceived well-being, while scores below 50 have been linked to significant psychological distress.

From baseline to 3 months after enrollment.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in Quality of Life at 3 and 6 months.
Tidsramme: From baseline to 3 and 6 months after enrollment.

Change from baseline in Quality of Life (EuroQol Five-Dimension Five-Level questionnaire, EQ-5D-5L).

Score range: 0 to 1 (index value). Higher scores indicate better quality of life.

Change from baseline in Quality of Life (EuroQol Visual Analogue Scale). Score range: 0 to 100. Higher scores indicate better self-rated health.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Life Satisfaction at 3 and 6 months.
Tidsramme: From baseline to 3 and 6 months after enrollment.

Change from baseline in Life Satisfaction (Life Satisfaction Questionnaire, LiSat-11) at 3 and 6 months.

Score range: 11 to 66. Higher scores indicate greater life satisfaction. Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Anxiety at 3 and 6 months.
Tidsramme: From baseline to 3 and 6 months after enrollment.

Change from baseline in Anxiety (Generalised Anxiety Disorder 7-item scale, GAD-7) at 3 and 6 months.

Score range: 0 to 21. Higher scores indicate more severe anxiety symptoms.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Depression at 3 and 6 months.
Tidsramme: From baseline to 3 and 6 months after enrollment.

Change from baseline in Depression (Patient Health Questionnaire 9-item scale, PHQ-9) at 3 and 6 months. Score range: 0 to 27. Higher scores indicate more severe depressive symptoms.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Post-Traumatic Stress at 3 and 6 months.
Tidsramme: From baseline to 3 and 6 months after enrollment.

Change from baseline in Post-Traumatic Stress (Impact of Event Scale - Revised, IES-R) at 3 and 6 months. Score range: 0 to 88. Higher scores indicate more severe post-traumatic stress symptoms.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Fatigue at 3 and 6 months.
Tidsramme: From baseline to 3 and 6 months after enrollment.

Change from baseline in Fatigue (Modified Fatigue Impact Scale, MFIS-21) at 3 and 6 months. Score range: 0 to 84. Higher scores indicate greater impact of fatigue.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Sleep at 3 and 6 months.
Tidsramme: From baseline to 3 and 6 months after enrollment.

Change from baseline in Sleep (Minimal Insomnia Symptom Scale, MISS) at 3 and 6 months. Score range: 0 to 12. Higher scores indicate more severe insomnia symptoms.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Cognitive Function at 3 and 6 months.
Tidsramme: From baseline to 3 months after enrollment.

Change from baseline in Cognitive Function (single-item question on perceived cognitive difficulties) at 3 and 6 months. Score range: 1 to 5. Higher scores indicate greater perceived cognitive impairment.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 months after enrollment.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. november 2025

Primær fullføring (Antatt)

31. mai 2028

Studiet fullført (Antatt)

31. august 2028

Datoer for studieregistrering

Først innsendt

14. november 2025

Først innsendt som oppfylte QC-kriteriene

18. november 2025

Først lagt ut (Faktiske)

21. november 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data (IPD) will be made available to members of the research team after the principal investigator has completed blinded analyses of the primary and secondary outcomes. Data will be stored securely and access will be restricted to authorized collaborators under data use agreements.

IPD-delingstidsramme

Beginning after completion of the blinded primary and secondary outcome analyses by the principal investigator, with no defined end date.

Tilgangskriterier for IPD-deling

Access to de-identified individual participant data (IPD) will be granted to members of the research team after completion of the blinded analysis of primary and secondary outcomes by the principal investigator. Each researcher must submit a brief description of the planned analyses and sign a data use agreement outlining responsibilities for data handling, confidentiality, and publication ethics. Access requests will be reviewed and approved by the principal investigator.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ANALYTIC_CODE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere